Who
Mark Sullivan
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Definium Therapeutics; General Counsel & Secretary, Sesen Bio; Gen Counsel, CCO & Secretary, MedQuist Holdings.
In numbers
- Trades disclosed
- 42
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $3.4M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 11 Jul 2011
- Last trade
- 25 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $514K14,051 at $36.57 | filing |
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $514K14,051 at $36.57 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $586K13,008 at $45.03 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $586K13,008 at $45.03 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 25 Mar 2026filed 26 Mar 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $198K10,702 at $18.47 | filing |
| 25 Mar 2026filed 26 Mar 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $198K10,702 at $18.47 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 26 Dec 2025filed 29 Dec 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $148K11,276 at $13.15 | filing |
| 25 Sep 2025filed 26 Sep 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $110K11,278 at $9.77 | filing |
| 25 Jun 2025filed 26 Jun 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K11,491 at $6.80 | filing |
| 25 Mar 2025filed 26 Mar 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $44K6,576 at $6.74 | filing |
| 12 Mar 2025filed 13 Mar 2025 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 26 Dec 2024filed 27 Dec 2024 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K4,519 at $7.43 | filing |
News
No headline names them, or the companies they trade most, lately.